Adoptive cellular immunotherapy for viral diseases

Bone Marrow Transplantation

Volumn 41, Issue 2, 2008, Pages 193-198

  Fujita, Y ^a   Rooney, C M ^a   Heslop, H E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CIDOFOVIR; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOTOXIN; RITUXIMAB; THYMIDINE KINASE;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOIMMUNITY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES VIRUS INFECTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION CONTROL; INFECTION PREVENTION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REMISSION; REVIEW; SUICIDE GENE THERAPY; T CELL DEPLETION; TREATMENT FAILURE; VIRUS INFECTION; VIRUS REACTIVATION;

CHILD; DNA VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES, CYTOTOXIC; VIRUS LATENCY;

EID: 38849159100     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705906     Document Type: Review

References (38)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558.
2. Young LS, Rickinson AB. Epstein-Barr virus:40 years on. Nat Rev Cancer 2004; 4: 757-768.
3. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999; 94 2208-2216.
4. Cohen JM, Cooper N, Chakrabarti S, Thomson K, Samarasinghe S, Cubitt D et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007; 48: 256-269.
5. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874-2880.
6. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK et al CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502-1505.
7. Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME et al Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007; 7: 1648-1655.
8. Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE et al Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005; 36: 1001-1008.
9. Feuchtinger T, Lucke J, Hamprecht K, Richard C, Handgretinger R, Schumm M et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2005; 128: 503-509.
10. Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE et al. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 677-686.
11. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232-1240.
12. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44.
13. Gillespie GM, Wills MR, Appay V, O'Callaghan C, Murphy M, Smith N et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000; 74: 8140-8150.
14. Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999; 162: 1827-1835.
15. Papadopoulos EB, Ladanyi M, Emanuel D, MacKinnon S, Boulad F, Carabasi MH et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.
16. Hromas R, Cornetta K, Srour E, Blanke C, Broun ER. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994; 84: 1689-1690.
17. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994; 331: 679-680.
18. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M et al Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007; 109: 4698-4707.
19. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK et al An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247-4254.
20. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360: 130-137.
21. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108: 1797-1808.
22. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R et al Selective depletion of alloreactive donor lymphocytes: A novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106: 1123-1129.
23. Rooney CM, Smith CA, Ng CYC, Loftin SK, Sixbey JW, Gan Y-J et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
24. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807-814.
25. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654-3661.
26. Imashuku S, Goto T, Matsumura T, Naya M, Yamori M, Hojo M et al. Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant 1998; 20: 337-340.
27. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131.
28. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
29. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J et al Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3922.
30. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375-1377.
31. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H et al Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379-386.
32. Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 707-714.
33. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64-76.
34. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166.
35. Rooney CM, Smith CA, Ng C, Loftin SK, Li C, Krance RA et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
36. Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-555.
37. Gottschalk S, Ng CYC, Smith CA, Perez M, Sample C, Brenner MK et al An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 2001; 97: 835-843.
38. Gandhi MK, Wilkie GM, Dua U, Mollee PN, Grimmett K, Williams T et al Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007; 7: 1293-1299.